<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149801">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150123</url>
  </required_header>
  <id_info>
    <org_study_id>V98_06</org_study_id>
    <nct_id>NCT01150123</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women</brief_title>
  <official_title>A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of study subjects in each study group that meets or exceeds specified GBS serotype-specific antibody levels (determined by ELISA) one month and one year after the last injection</measure>
    <time_frame>2 months post last injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The GMC and GMR (and associated 95% CI) for GBS serotype-specific antibody responses one month and one year after last injection for each study group</measure>
    <time_frame>2 months post last injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited local and systemic reactions, AEs, and SAEs</measure>
    <time_frame>2 months post last vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Group B Streptococcus</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high and low dose versus presence or absence of adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two different doses of alternate adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single active vaccine injection vs two active vaccine injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus (GBS) vaccine</intervention_name>
    <description>The study will include two enrollment groups (340 subjects each). Each enrollment group will evaluate a high and low dose versus the presence or absence of adjuvant</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus (GBS) vaccine</intervention_name>
    <description>Each enrollment group will evaluate a high and low dose versus dose of adjuvant</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus (GBS) vaccine</intervention_name>
    <description>Half of all vaccine recipients will receive a single active vaccine injection and half will receive two identical active vaccine injections (1 month apart)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>A placebo group who receive saline will be included in each enrollment group</description>
    <arm_group_label>Arm 4: placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females 18-40 years of age inclusive.

        Exclusion Criteria:

          -  Individuals who are pregnant or nursing.

          -  Individuals who have had a previous immunization with a vaccine containing
             streptococcus antigens or any vaccine within 30 days of enrollment through 30 days of
             study completion.

          -  Individuals with a history of severe allergic reactions after previous vaccination

          -  Individuals with designated blood tests that are not within normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 16, 2012</lastchanged_date>
  <firstreceived_date>March 31, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Group B streptococcus</keyword>
  <keyword>GBS</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Group B streptococcus (GBS) disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
